Axitinib injectable suspension phase 1/2a trial enrolls first patients

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Amydis announces successful pre-IND meeting with FDA to develop retinal tracer for amyloid angiopathy diagnosis

Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.

Saving the world: Pharmaceutical innovation in nine months

The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.